Fig. 1.
Immunogenicity of CEA694–702WT and analog peptide in HLA-A*0201 healthy donors. a PBMCs from three HLA-A*0201 healthy donors were stimulated first with peptide-pulsed autologous matured dendritic cells and two consecutive times with irradiated T2-cells pulsed with peptide CEA694–702WT. The presence of peptide-specific CD8+ T-cells was assessed by multiparameter flow cytometry analysis 1 week after the last restimulation on cultured cells labeled with anti-CD4 mAb and A2/CEA694–702 multimers. b Representative results from PBMC of one HLA-A*0201 healthy donor stimulated with peptide CEA694–702L2 (left), CEA694–702V9 (center), and CEA694–702L2V9 (right) independently. Flow cytometry analysis was performed after three rounds of in vitro stimulation with anti-CD8 mAb and the corresponding A2/cognate peptide multimers